Overview

Monotherapy of Itraconazole Versus Prednisolone in Allergic Bronchopulmonary Aspergillosis

Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to evaluate the efficacy and safety of itraconazole monotherapy in patients with ABPA.
Phase:
Phase 2/Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Postgraduate Institute of Medical Education and Research
Treatments:
Fluticasone
Formoterol Fumarate
Glucocorticoids
Hydroxyitraconazole
Itraconazole
Methylprednisolone
Methylprednisolone acetate
Methylprednisolone Hemisuccinate
Prednisolone
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate
Criteria
Inclusion Criteria: Patients will be included in the study if they meet the criteria for
ABPA defined by

Presence of all the following three criteria:

- immediate cutaneous hyperreactivity on aspergillus skin test

- elevated total IgE levels > 1000 IU/mL

- A fumigatus specific IgE levels > 0.35 kU/L

Two of the following criteria:

- presence of serum precipitating antibodies against A fumigatus

- fixed or transient radiographic pulmonary opacities

- absolute eosinophil count > 1000/µL

- central bronchiectasis on HRCT.

Exclusion Criteria:

- if they have taken glucocorticoids for more than three weeks in the preceding six
months

- failure to give informed consent

- enrollment in another trial of ABPA